Chennai, Oct 27: MGM Cancer Institute organised a two-day-long conference on bone marrow transplantation and cellular therapies called ‘MGM HCON 2026’. More than 150 specialists and delegates from various parts of the country took part in the conference.
The conference explored developments across adult and paediatric haematology, haematological oncology, and cellular therapies including CAR T-cell therapy. Sessions provided a forum for clinicians to share knowledge, discuss evolving treatment approaches and consider how collaboration across specialties can support care for patients with complex blood disorders and cancers. A significant institutional milestone recognised during the conference was MGM Cancer Institute’s completion of 100 bone marrow transplantation (BMT) procedures in two years.
Dr. Gopinathan, Consultant in Haemato-Oncology and Bone Marrow Transplantation and Organising Secretary of MGM HCON 2026 said,
“MGM HCON 2026 plays a vital role in keeping the clinics updated about the recent haematological advancements. Since haematological guidelines are dynamic and keep upgrading once in six months, the academic connect programme will help clinicians to manage patients with the utmost recent clinical evidence, resulting in improved patient outcomes.”
He further added
“Reaching the milestone of 100 bone marrow transplantation procedures in two years reflects the dedication, expertise and collaborative efforts of our multidisciplinary team. Every transplant represents a patient’s journey and the collective commitment of healthcare professionals working towards better outcomes.
Prof. M. B. Agarwal, President of the Mumbai Haematology Group, Bombay Hospital participated as the chief guest in the conference. Addressing the gathering, he said,
“Scientific progress in haematology depends on continuous learning, collaboration and the exchange of clinical knowledge. Platforms such as MGM HCON encourage meaningful discussions among specialists and help advance approaches to patient care.”
In his comments, Dr. Deenadayalan, HOD and Clinical Lead, Paediatric Haematology, Oncology, Blood and Marrow Transplantation, MGM Cancer Institute said,
“Advances in paediatric haematology and bone marrow transplantation bring new possibilities for children and their families. By bringing experts together, MGM HCON encourages the sharing of knowledge and clinical experiences that can help us continually improve treatment, supportive care and outcomes for our young patients”.
Mr. Saravana Kumar Rajan, Unit Chief Operating Officer, MGM Cancer Institute, said,
“At MGM Cancer Institute, we believe that clinical excellence is strengthened through collaboration, continuous learning and a shared commitment to patients. MGM HCON reflects our efforts to bring expertise together, encourage scientific dialogue and support advancements that can make a meaningful difference to patient care.”
